Liqiang Feng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/866528/publications.pdf

Version: 2024-02-01

		567144	642610	
23	1,294	15	23	
papers	citations	h-index	g-index	
23	23	23	2723	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerging Microbes and Infections, 2020, 9, 940-948.	3.0	414
2	An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nature Communications, 2020, 11, 4207.	5.8	194
3	Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nature Communications, 2021, 12, 4984.	5.8	100
4	Visualizing influenza virus infection in living mice. Nature Communications, 2013, 4, 2369.	5.8	92
5	Cell transcriptomic atlas of the non-human primate Macaca fascicularis. Nature, 2022, 604, 723-731.	13.7	81
6	Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China. Vaccine, 2011, 29, 3837-3841.	1.7	56
7	Mucosal Priming with a Replicating-Vaccinia Virus-Based Vaccine Elicits Protective Immunity to Simian Immunodeficiency Virus Challenge in Rhesus Monkeys. Journal of Virology, 2013, 87, 5669-5677.	1.5	55
8	Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein. Npj Vaccines, 2018, 3, 29.	2.9	38
9	Generation of Replication-Competent Recombinant Influenza A Viruses Carrying a Reporter Gene Harbored in the Neuraminidase Segment. Journal of Virology, 2010, 84, 12075-12081.	1.5	31
10	Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model. Emerging Microbes and Infections, 2019, 8, 749-759.	3.0	26
11	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerging Microbes and Infections, 2021, 10, 1097-1111.	3.0	25
12	Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. Emerging Microbes and Infections, 2017, 6, 1-8.	3.0	24
13	Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection. Journal of Virology, 2022, 96, JVI0160021.	1.5	24
14	Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity. Virology, 2018, 518, 272-283.	1.1	20
15	Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. Human Vaccines and Immunotherapeutics, 2015, 11, 1803-1813.	1.4	18
16	Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fc $<$ b $>$ $\hat{l}^3 <$ /b $>$ Receptor-Dependent and -Independent Pathways. MBio, 2021, 12, .	1.8	17
17	An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerging Microbes and Infections, 2018, 7, 1-12.	3.0	16
18	Human Desmoglein-2 and Human CD46 Mediate Human Adenovirus Type 55 Infection, but Human Desmoglein-2 Plays the Major Roles. Journal of Virology, 2020, 94, .	1.5	15

LIQIANG FENG

#	Article	IF	CITATIONS
19	Longitudinal analysis of the antibody repertoire of a Zika virus-infected patient revealed dynamic changes in antibody response. Emerging Microbes and Infections, 2020, 9, 111-123.	3.0	13
20	Immunization with an adenovirus-vectored TB vaccine containing Ag85A-Mtb32 effectively alleviates allergic asthma. Journal of Molecular Medicine, 2018, 96, 249-263.	1.7	12
21	Seroprevalence of Neutralizing Antibodies to Human Adenovirus Type 4 and 7 in Healthy Populations From Southern China. Frontiers in Microbiology, 2018, 9, 3040.	1.5	12
22	Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice. Journal of Virology, 2021, 95, .	1.5	6
23	A Live-Attenuated Zika Virus Vaccine with High Production Capacity Confers Effective Protection in Neonatal Mice. Journal of Virology, 2021, 95, e0038321.	1.5	5